Breaking News, Collaborations & Alliances

MAX Biopharma and Metaba Partner to Study Metabolomics

Will empower MAX BioPharma in its R&D efforts to develop novel drugs for some of the most debilitating and fatal diseases in humans.

Author Image

By: Charlie Sternberg

Associate Editor

MAX BioPharma Inc. and Metaba LLC have partnered to study the effects of oxysterol drug candidates that target non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), chronic inflammation, and atherosclerosis on metabolic processes using Metaba’s metabolomics platform technology.   The two companies will identify changes in metabolites induced by oxysterols that may not only further evaluate the mechanism of action for their therapeutic effects, but also identify poten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters